cell dati finanziari 09/03/06

bravi a farci bannare per l'ennesima volta!
:clap: :clap: :clap: :clap: :clap:
io posso seguire fino alle 14,45-15.00.........qualcuno mi potrebbe tenere aggiornato,via cell.?
:D ..speriamo in una bella sospensione al rialzo...e che la aprono direttamente domani a 2.5 euro :D
perchè ci hanno bannato?????

matrix_32 ha scritto:
purtroppo ho 3...........
posso kiamare il mio tol al call center ma mi costa più o meno 1,5 euro........

e non mi danno nemmeno la quot. al nasdaq!!!! :angry: :angry: :angry:

tranquillo di solito quando c'è qualcosa di grosso negli USA già scambiano o il BOOK di INET è piazzato :yes: x ora NULLA di NULLA mentre in Italia il solito BACCANO :yes:
Raga qualcuno saprebbe dirmi se la conference dell 14 30 si puo' seguire su qualche Tv?
Se si quale? Grazie
Orma68 ha scritto:
Raga qualcuno saprebbe dirmi se la conference dell 14 30 si puo' seguire su qualche Tv?
Se si quale? Grazie
non credo .........credo ke la si possa ascoltare tramite pc.
Cell Therapeutics, Inc. (CTI) Reports 2005 Fourth Quarter and Year End Results
SEATTLE, March 9 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTAX) reported financial results for the quarter and year ended December 31, 2005. Total revenues for the quarter were $1.2 million compared to $8.1 million in the fourth quarter of 2004. CTI reported a net loss for the quarter of $18.7 million ($0.27 per share) compared to a net loss of $43.5 million ($0.72 per share) for the same period in 2004. This included a $40.7 million gain in the quarter on the divestiture of TRISENOX(R) and a $23.6 million charge for the conversion of $38.4 million related to the Company's 4% and 5.75% convertible senior subordinated notes.

Total revenues for the year ended December 31, 2005, were $16.1 million compared to $29.6 million in 2004. For the year, CTI posted a net loss of $102.5 million ($1.59 per share), including a $71.2 million gain for the year on the divestiture of TRISENOX, compared to a net loss of $252.3 million ($4.67 per share) in 2004, which included an $87.4 million charge related to in-process research and development resulting from the acquisition of Novuspharma S.p.A..

Revenues for the quarter and year ended December 31, 2005 were lower as compared to the same periods in 2004 due to a reduction in product sales revenues as a result of the divestiture of TRISENOX to Cephalon in July 2005. The Company ended the year with cash, cash equivalents, securities available-for-sale and interest receivable of approximately $69 million. This amount excludes proceeds of $24.6 million held in escrow until April 30, 2006 to fund potential redemptions of 30% of the 6.75% convertible senior notes.

As of February 28, 2006, $56.1 million of the 6.75% convertible senior notes had converted into approximately 21.3 million shares. As a result of the conversions we paid make whole interest of $18.9 million.

"Our efforts to reduce expenses and raise additional capital over the last several months have placed us in the position this year to focus on advancing XYOTAX(TM) toward marketing applications in the United States and Europe and on reporting the interim analysis for the pixantrone phase III trial in non-Hodgkin's lymphoma," stated James A. Bianco, M.D., President and CEO of CTI.

2005 Highlights

-- Completed an $82 million convertible senior notes offering and
conversion of $38.4 million of outstanding 5.75% and 4% convertible
senior subordinated notes

-- Announced that pixantrone achieved the primary endpoint of a
randomized trial, significantly prolonging time to progression when
added to rituximab compared to rituximab alone, in indolent
non-Hodgkin's lymphoma

-- Reported gender specific survival benefit observed in STELLAR 3 and
4 trials among women on XYOTAX, linking survival benefit to estrogen
status and metabolism of polymer

-- Reported prospective analysis of phase II trial (PGT202)
demonstrating estrogen-linked survival benefit for women with
non-small cell lung cancer on XYOTAX

-- Initiated first gender specific approval trial (PIONEER trial) in
non-small cell lung cancer

-- Significantly reduced operating costs compared to 2004 and refocused
resources on near term XYOTAX and pixantrone milestones

-- Completed the divestiture of TRISENOX to Cephalon, and recorded a
$71.2 million gain for the year, with the potential to earn an
additional $100 million in milestones

-- Appointed Stonefield Josephson, Inc. as independent registered public
accounting firm

-- Appointed John Bauer, former Nintendo of America, Inc. Executive Vice
President of Finance, as new board member and Chair of the Company's
Audit Committee and appointed Phil Nudelman as Chairman of the Board

-- Announced initiation by the Gynecologic Oncology Group (GOG) of a
large phase III clinical trial examining the ability of XYOTAX to
maintain remission and prolong the survival of ovarian
cancer patients

-- Announced XYOTAX patent allowance in Japan, which will provide
exclusivity until 2018; announced that the European Patent Office
issued an allowance for a patent directed to XYOTAX, which when
issued, will have the same term as existing U.S. patents that provide
patent protection for XYOTAX until 2017
personalmente dati migliori del previsto
raga in inglese non ci capisco nulla...ma qcosa di buono dev'esserci visto ke il titolo ha fatto un balzo da 1,68 a 1,72 quasi........
Tp..............2 €